Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hailai Xinchuang Closes $77 Million Round for Tumor Treating Fields Device

publication date: Jul 16, 2021

Jiangsu Hailai Xinchuang Medical Technology closed a $77 million Series C funding to advance its Tumor Treating Fields (TTF) electrical pulse technology for cancer. TTF is designed to interfere with cancer cell division. Hailai has started a multi-center China clinical trial of EFE-G100 in glioblastoma patients, with positive initial results. The company will report an interim analysis from the data in 2022. The latest funding was led by YF Capital, with participation from Temasek, Lilly Asia Ventures, 3H Health Investment, CITIC and Qiming. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here